Krystal Biotech Inc (KRYS) | Stock Price, Analysis, News, Fundaments & Technical Information

stock

Krystal Biotech Inc

NASDAQ | KRYS

178.13

USD

-2.87 (-1.59%)

AT CLOSE (AS OF Apr 3, 2025)

$5.2B

MARKET CAP

60.33

P/E Ratio

EPS

$219

52 Week High

$142

52 Week Low

LIFE SCIENCES

Sector

KRYS Chart

Area

Trade Smarter

Take control of your trading journey with a set of smart tools for serious trades

Backtests

Strategy Backtester designed to automate your backtesting and revolutionize the way you trade

Learn More About Backtests

Scanner

Leverage the power of AI to detect valuable opportunities and gain the most out of the markets.

Learn More About Scanner

Signals

Automate your trading workflow with AI-powered trading signals to execute trades automatically.

Learn More About Signals

Journal

Record your trades and performance to improve your trading with AfterPullback’s Trading Journal

Learn More About Journal

KRYS Technicals

Tags:

KRYS Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$183M
Total Revenue	$297M
Cost Of Revenue	$114M
Costof Goods And Services Sold	$20M
Operating Income	$66M
Selling General And Administrative	$114M
Research And Development	$54M
Operating Expenses	$225M
Investment Income Net	-
Net Interest Income	$30M
Interest Income	$30M
Interest Expense	-
Non Interest Income	$291M
Other Non Operating Income	-
Depreciation	$6M
Depreciation And Amortization	$6.7M
Income Before Tax	$95M
Income Tax Expense	$6.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	$89M
Comprehensive Income Net Of Tax	$88M
Ebit	$66M
Ebitda	$110M
Net Income	$89M

Revenue & Profitability

Earnings Performance

KRYS Financials

Highlights

Balance Sheet

Cash Flow

Income Statement

Yearly

Quarterly

yearly Balance Sheet (As of Dec 31, 2024)

Field	Value (USD)
Total Assets	$1.1B
Total Current Assets	$742M
Cash And Cash Equivalents At Carrying Value	$345M
Cash And Short Term Investments	$598M
Inventory	$27M
Current Net Receivables	$105M
Total Non Current Assets	$314M
Property Plant Equipment	$155M
Accumulated Depreciation Amortization Ppe	$22M
Intangible Assets	-
Intangible Assets Excluding Goodwill	-
Goodwill	-
Investments	$405M
Long Term Investments	$152M
Short Term Investments	$253M
Other Current Assets	$13M
Other Non Current Assets	$231K
Total Liabilities	$109M
Total Current Liabilities	$102M
Current Accounts Payable	$5M
Deferred Revenue	-
Current Debt	-
Short Term Debt	$1.2M
Total Non Current Liabilities	$7.4M
Capital Lease Obligations	$7.3M
Long Term Debt	-
Current Long Term Debt	-
Long Term Debt Noncurrent	-
Short Long Term Debt Total	$7.3M
Other Current Liabilities	$2.4M
Other Non Current Liabilities	$1.4M
Total Shareholder Equity	$946M
Treasury Stock	-
Retained Earnings	-$181M
Common Stock	$0
Common Stock Shares Outstanding	$29M

yearly Cash Flow (As of Dec 31, 2024)

Field	Value (USD)
Operating Cashflow	$123M
Payments For Operating Activities	-
Proceeds From Operating Activities	-
Change In Operating Liabilities	$2.4M
Change In Operating Assets	$84M
Depreciation Depletion And Amortization	$6M
Capital Expenditures	$4.2M
Change In Receivables	$63M
Change In Inventory	$12M
Profit Loss	$89M
Cashflow From Investment	-$163M
Cashflow From Financing	$27M
Proceeds From Repayments Of Short Term Debt	-
Payments For Repurchase Of Common Stock	-
Payments For Repurchase Of Equity	-
Payments For Repurchase Of Preferred Stock	-
Dividend Payout	-
Dividend Payout Common Stock	-
Dividend Payout Preferred Stock	-
Proceeds From Issuance Of Common Stock	$0
Proceeds From Issuance Of Long Term Debt And Capital Securities Net	-
Proceeds From Issuance Of Preferred Stock	-
Proceeds From Repurchase Of Equity	$32M
Proceeds From Sale Of Treasury Stock	-
Change In Cash And Cash Equivalents	-
Change In Exchange Rate	-
Net Income	$89M

yearly Income Statement (As of Dec 31, 2024)

Field	Value (USD)
Gross Profit	$183M
Total Revenue	$297M
Cost Of Revenue	$114M
Costof Goods And Services Sold	$20M
Operating Income	$66M
Selling General And Administrative	$114M
Research And Development	$54M
Operating Expenses	$225M
Investment Income Net	-
Net Interest Income	$30M
Interest Income	$30M
Interest Expense	-
Non Interest Income	$291M
Other Non Operating Income	-
Depreciation	$6M
Depreciation And Amortization	$6.7M
Income Before Tax	$95M
Income Tax Expense	$6.2M
Interest And Debt Expense	-
Net Income From Continuing Operations	$89M
Comprehensive Income Net Of Tax	$88M
Ebit	$66M
Ebitda	$110M
Net Income	$89M

KRYS Profile

Krystal Biotech Inc Profile

Sector: LIFE SCIENCES

Industry: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.

Symbol	Price	Change %	Market Cap	Volume
DMN	$0.02	13.04%	-	706,860,781
NVDA	$101.80	-7.81%	$2.68T	334,149,797
INTC	$22.43	2.05%	$95.85B	240,924,655
F	$9.55	-5.96%	$39.53B	213,326,329
LCID	$2.32	-3.33%	$7.67B	210,875,217

Symbol	Price	Change %	Market Cap	Volume
JNJ	$160.56	3.35%	$399.65B	9,908,361
PG	$172.57	1.81%	$399.61B	6,993,394
NVO	$67.12	-1.65%	$308.32B	8,797,694
AZN	$74.03	2.50%	$225.70B	6,150,517
MRK	$86.38	-0.25%	$220.07B	12,113,104

Symbol	Price	Change %	Market Cap	Volume
VCIG	$6.06	1,818.33%	$26.40M	302,396
MKTW	$9.19	1,684.81%	$19.91M	117,875
ICCT	$4.38	111.59%	$9.78M	168,784,937
PTIX	$0.42	84.14%	$4.04M	177,332,811
MRM	$0.65	74.84%	$2.91M	51,693,935

Symbol	Price	Change %	Market Cap	Volume
ALDX	$1.42	-73.33%	$326.91M	21,865,554
RFAC	$2.70	-68.60%	$8.44M	605,339
PKBO	$0.02	-67.86%	$531.87K	66,140
TCBP	$0.50	-67.53%	$360.37K	1,955,586
OMQS	$0.04	-66.36%	$1.50M	950,669

Quick Links

KRYS $178.13 (-1.59%) Quote details